Navigation Links
AMDL Announces Investor Relations Presentation Available on Website
Date:7/3/2008

TUSTIN, Calif., July 3 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a world leader in specialty pharmaceuticals headquartered in Tustin, Ca., with operations in Shenzhen, Jiangxi, and Jilin, China, announced today it has released its investor presentation which is available for viewing on the Company's website at http://www.amdl.com.

About AMDL:

AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.

About Jade Pharmaceutical:

JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(206) 310-5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nabriva Therapeutics Announces Appointment of New CEO
2. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
3. Biopure Announces Private Equity Financing
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
7. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
8. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
9. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
10. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
11. China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Okyanos Cell ... seminar as part of their live events series, “Stem Cell Therapy: The Next Phase ... facility under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... , more than tripling its goal and raising over $30,000 in the first ... that grows nutritious veggies & herbs fast, easy, and affordably, anywhere. , “Simply ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
Breaking Biology News(10 mins):